XmAb® bispecific antibodies
GPTKB entity
Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
bispecific antibody
|
| gptkbp:barrelLength |
CD3
tumor-associated antigens |
| gptkbp:benefits |
enhanced efficacy
increased specificity reduced off-target effects |
| gptkbp:clinicalTrials |
ongoing
Phase 1 Phase 2 Phase 3 promising results |
| gptkbp:collaboratedWith |
pharmaceutical companies
|
| gptkbp:compatibleWith |
T cell activation
cytokine release tumor cell lysis |
| gptkbp:developedBy |
gptkb:Xencor
|
| gptkbp:dosageForm |
varies by trial
|
| gptkbp:firstClaim |
autoimmune diseases
|
| gptkbp:firstIntroduced |
2014
|
| gptkbp:formulation |
intravenous infusion
|
| gptkbp:hasPopulation |
varied demographics
|
| gptkbp:historicalResearch |
long-term effects
combination therapies mechanistic studies patient selection criteria biomarker_identification |
| https://www.w3.org/2000/01/rdf-schema#label |
XmAb® bispecific antibodies
|
| gptkbp:market |
high
|
| gptkbp:patentCitation |
gptkb:Xencor
|
| gptkbp:producedBy |
recombinant DNA technology
|
| gptkbp:productionCompany |
preclinical
|
| gptkbp:regulatoryCompliance |
investigational
|
| gptkbp:research |
grants
investments |
| gptkbp:research_areas |
oncology
immunology |
| gptkbp:researchAndDevelopment |
improved survival rates
enhanced immune response reduced tumor burden |
| gptkbp:researchFocus |
immuno-oncology
|
| gptkbp:researchInterest |
academic collaborations
|
| gptkbp:safetyFeatures |
monitored
|
| gptkbp:sideEffect |
immune-related adverse events
|
| gptkbp:targets |
solid tumors
hematological malignancies multiple antigens |
| gptkbp:triggerType |
dual targeting
redirect T cells to cancer cells |
| gptkbp:type |
therapeutic antibody
|
| gptkbp:usedFor |
cancer treatment
|